Do analysts rate HBIO or LMNX?

Harvard Bioscience presently has a consensus target price of $6.00, suggesting a potential downside of 4.38%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Defiance Daily Target 2X Long LMND ETF. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Defiance Daily Target 2X Long LMND ETF 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, WAT or HBIO?

Waters has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Waters $4.64B 8.45 $642.63M $4.01 99.63 Harvard Bioscience $85.53M 0.33 -$56.70M -$2.17 N/A

Harvard Bioscience (HBIO) Competitors

$6.28 +0.09 (+1.37%)

As of 10:22 AM Eastern

Compare

HBIO vs. LMNX, TMO, A, WAT, and ILMN

Should you buy Harvard Bioscience stock or one of its competitors? MarketBeat compares Harvard Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harvard Bioscience include Defiance Daily Target 2X Long LMND ETF (LMNX), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Waters (WAT), and Illumina (ILMN). These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Harvard Bioscience (NASDAQ:HBIO) and Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) are related small-cap companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Harvard Bioscience has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Defiance Daily Target 2X Long LMND ETF has a beta of -16.23, indicating that its share price is 1,723% less volatile than the broader market.

In the previous week, Defiance Daily Target 2X Long LMND ETF had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 1 mentions for Defiance Daily Target 2X Long LMND ETF and 0 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.00 equaled Defiance Daily Target 2X Long LMND ETF'saverage media sentiment score.

Company	Overall Sentiment
Harvard Bioscience	Neutral
Defiance Daily Target 2X Long LMND ETF	Neutral

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$85.53M	0.33	-$56.70M	-$2.17	N/A
Defiance Daily Target 2X Long LMND ETF	$437.66M	0.01	$15.17M	$0.51	17.59

Harvard Bioscience presently has a consensus target price of $6.00, suggesting a potential downside of 4.38%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Defiance Daily Target 2X Long LMND ETF.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Defiance Daily Target 2X Long LMND ETF	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 87.8% of Defiance Daily Target 2X Long LMND ETF shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by company insiders. Comparatively, 6.6% of Defiance Daily Target 2X Long LMND ETF shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Harvard Bioscience's net margin of -11.44%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.44%	-25.78%	-4.37%
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%

Summary

Defiance Daily Target 2X Long LMND ETF beats Harvard Bioscience on 9 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Harvard Bioscience (NASDAQ:HBIO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

In the previous week, Thermo Fisher Scientific had 29 more articles in the media than Harvard Bioscience. MarketBeat recorded 29 mentions for Thermo Fisher Scientific and 0 mentions for Harvard Bioscience. Thermo Fisher Scientific's average media sentiment score of 1.35 beat Harvard Bioscience's score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Overall Sentiment
Thermo Fisher Scientific	Positive
Harvard Bioscience	Neutral

Thermo Fisher Scientific has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Thermo Fisher Scientific currently has a consensus price target of $619.41, indicating a potential upside of 5.94%. Harvard Bioscience has a consensus price target of $6.00, indicating a potential downside of 4.38%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, research analysts clearly believe Thermo Fisher Scientific is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.79
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$46.34B	4.67	$6.70B	$18.59	31.45
Harvard Bioscience	$85.53M	0.33	-$56.70M	-$2.17	N/A

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Thermo Fisher Scientific has a net margin of 15.04% compared to Harvard Bioscience's net margin of -11.44%. Thermo Fisher Scientific's return on equity of 17.09% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.04%	17.09%	8.12%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 15 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Agilent Technologies?

Harvard Bioscience (NASDAQ:HBIO) and Agilent Technologies (NYSE:A) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Harvard Bioscience has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$85.53M	0.33	-$56.70M	-$2.17	N/A
Agilent Technologies	$6.95B	5.84	$1.30B	$4.98	28.84

In the previous week, Agilent Technologies had 13 more articles in the media than Harvard Bioscience. MarketBeat recorded 13 mentions for Agilent Technologies and 0 mentions for Harvard Bioscience. Agilent Technologies' average media sentiment score of 1.32 beat Harvard Bioscience's score of 0.00 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Harvard Bioscience	Neutral
Agilent Technologies	Positive

Harvard Bioscience presently has a consensus target price of $6.00, suggesting a potential downside of 4.38%. Agilent Technologies has a consensus target price of $159.35, suggesting a potential upside of 10.95%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89

80.9% of Harvard Bioscience shares are owned by institutional investors. 17.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Agilent Technologies has a net margin of 19.55% compared to Harvard Bioscience's net margin of -11.44%. Agilent Technologies' return on equity of 24.33% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.44%	-25.78%	-4.37%
Agilent Technologies	19.55%	24.33%	12.99%

Summary

Agilent Technologies beats Harvard Bioscience on 14 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Waters?

Waters (NYSE:WAT) and Harvard Bioscience (NASDAQ:HBIO) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Waters presently has a consensus price target of $418.10, suggesting a potential upside of 4.65%. Harvard Bioscience has a consensus price target of $6.00, suggesting a potential downside of 4.38%. Given Waters' stronger consensus rating and higher probable upside, analysts plainly believe Waters is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Waters	0 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.75
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

94.0% of Waters shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 0.3% of Waters shares are held by insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Waters had 32 more articles in the media than Harvard Bioscience. MarketBeat recorded 32 mentions for Waters and 0 mentions for Harvard Bioscience. Waters' average media sentiment score of 1.15 beat Harvard Bioscience's score of 0.00 indicating that Waters is being referred to more favorably in the media.

Company	Overall Sentiment
Waters	Positive
Harvard Bioscience	Neutral

Waters has a net margin of 3.58% compared to Harvard Bioscience's net margin of -11.44%. Waters' return on equity of 11.27% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Waters	3.58%	11.27%	6.73%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Waters has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Waters has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Waters	$4.64B	8.45	$642.63M	$4.01	99.63
Harvard Bioscience	$85.53M	0.33	-$56.70M	-$2.17	N/A

Summary

Waters beats Harvard Bioscience on 15 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Illumina?

Harvard Bioscience (NASDAQ:HBIO) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Harvard Bioscience presently has a consensus target price of $6.00, indicating a potential downside of 4.38%. Illumina has a consensus target price of $188.40, indicating a potential upside of 0.10%. Given Illumina's stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

Illumina has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$85.53M	0.33	-$56.70M	-$2.17	N/A
Illumina	$4.34B	6.54	$850M	$5.36	35.12

Harvard Bioscience has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Illumina has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

In the previous week, Illumina had 48 more articles in the media than Harvard Bioscience. MarketBeat recorded 48 mentions for Illumina and 0 mentions for Harvard Bioscience. Illumina's average media sentiment score of 0.82 beat Harvard Bioscience's score of 0.00 indicating that Illumina is being referred to more favorably in the news media.

Company	Overall Sentiment
Harvard Bioscience	Neutral
Illumina	Positive

80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by company insiders. Comparatively, 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Illumina has a net margin of 18.36% compared to Harvard Bioscience's net margin of -11.44%. Illumina's return on equity of 29.84% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.44%	-25.78%	-4.37%
Illumina	18.36%	29.84%	12.17%

Summary

Illumina beats Harvard Bioscience on 15 of the 17 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.30M	$9.27B	$6.97B	$12.95B
Dividend Yield	N/A	1.46%	2.59%	9.93%
P/E Ratio	-2.89	62.33	270.87	25.95
Price / Sales	0.33	107.04	666.62	110.60
Price / Cash	0.54	26.07	71.89	50.37
Price / Book	2.04	38.39	13.29	6.22
Net Income	-$56.70M	$56.66B	$3.45B	$342.81M
7 Day Performance	2.87%	3.23%	4.21%	3.97%
1 Month Performance	-5.35%	-0.63%	-1.96%	-1.33%
1 Year Performance	22.06%	19.42%	76.81%	21.98%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	0.8081 of 5 stars	$6.28 +1.4%	$6.00 -4.4%	+22.6%	$28.30M	$85.53M	N/A	490	Upcoming Earnings Gap Up
LMNX Defiance Daily Target 2X Long LMND ETF	N/A	$14.10 +0.4%	N/A	N/A	$5.36M	$437.66M	27.65	1,325	Gap Down
TMO Thermo Fisher Scientific	4.6114 of 5 stars	$577.32 +3.2%	$617.14 +6.9%	+28.9%	$214.54B	$44.56B	31.06	125,000	Positive News Analyst Forecast
A Agilent Technologies	4.7091 of 5 stars	$140.57 +1.9%	$159.35 +13.4%	+24.7%	$39.70B	$7.23B	28.23	18,100	Positive News
WAT Waters	3.0535 of 5 stars	$384.67 +3.6%	$401.60 +4.4%	+43.7%	$37.77B	$3.17B	48.88	7,900	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. LMNX, TMO, A, WAT, and ILMN

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Summary

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Summary

How does Harvard Bioscience compare to Agilent Technologies?

Summary

How does Harvard Bioscience compare to Waters?

Summary

How does Harvard Bioscience compare to Illumina?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. LMNX, TMO, A, WAT, and ILMN

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Which has more risk & volatility, HBIO or LMNX?

Does the media favor HBIO or LMNX?

Which has better earnings & valuation, HBIO or LMNX?

Do analysts rate HBIO or LMNX?

Do institutionals and insiders believe in HBIO or LMNX?

Is HBIO or LMNX more profitable?

Summary

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Does the media favor TMO or HBIO?

Which has more volatility and risk, TMO or HBIO?

Do analysts prefer TMO or HBIO?

Which has better earnings & valuation, TMO or HBIO?

Do institutionals & insiders believe in TMO or HBIO?

Is TMO or HBIO more profitable?

Summary

How does Harvard Bioscience compare to Agilent Technologies?

Which has more volatility & risk, HBIO or A?

Which has higher earnings & valuation, HBIO or A?

Does the media refer more to HBIO or A?

Do analysts rate HBIO or A?

Do insiders and institutionals have more ownership in HBIO or A?

Is HBIO or A more profitable?

Summary

How does Harvard Bioscience compare to Waters?

Do analysts recommend WAT or HBIO?

Do insiders & institutionals hold more shares of WAT or HBIO?

Does the media prefer WAT or HBIO?

Is WAT or HBIO more profitable?

Which has more risk and volatility, WAT or HBIO?

Which has preferable earnings and valuation, WAT or HBIO?

Summary

How does Harvard Bioscience compare to Illumina?

Do analysts prefer HBIO or ILMN?

Which has better earnings and valuation, HBIO or ILMN?

Which has more volatility and risk, HBIO or ILMN?

Does the media prefer HBIO or ILMN?

Do institutionals and insiders believe in HBIO or ILMN?

Is HBIO or ILMN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools